Backgroundː In this study, we aimed to examine the effect of Sodium Glucose Cotransporter 2 inhibitors (SGLT-2i) on routine laboratory test results at 12 weeks follow-up among type diabetes mellitus (T2D) patients using empagliflozin and dapagliflozin. Methodsː Three hundred ten with a diagnosis T2D (over 18 years age) SGLT-2i added stable triple combination therapy were included in study. Pati...

Remogliflozin has shown similar glycemic control to dapagliflozin in phase III study; however, its impact on variability (GV) was unknown. The objective evaluate the effect of remogliflozin

Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been shown to reduce the risk of cardiovascular death or worsening heart failure (HF), and improve symptom burden, physical function quality life in patients with HF reduced ejection fraction. The mechanisms benefits SGLT2 inhibitors, however, remain unclear. In this substudy DEFINE-HF trial, randomized dapagliflozin placebo had lung fluid ...

Abstract The sodium-glucose co-transporter (SGLT)-2 inhibitor dapagliflozin was recently reported to reduce renal tyrosine hydroxylase (TH) and norepinephrine levels, lowering blood pressure preventing endothelial dysfunction, in a murine model of neurogenic hypertension. This suggested that may combat sympathetic nervous system (SNS) hyperactivity, which is known accompany aggravate chronic he...

Following publication of the original article [1], the authors identified a number of errors. In Result (P.3), Table 1 (P.4), Table 5 (P.9) and Supplementary Table 1, the correct unit for adiponectin was μg/mL. In Table 1 (P.4), the correct value for the post treatment body weight in dapagliflozin was 76.2±14.8. In Table 6 (P.10), the correct value for the pre treatment sd LDL/LDL-C in decrease...

Abstract Background Trastuzumab has improved the prognosis in patients with HER2-positive breast cancer, but it can induce left ventricular dysfunction reduced ejection fraction or HF during treatment. Dapagliflozin is a SGLT2i cardio-renal benefits. In DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes Heart Failure) trial, sodium-glucose cotransporter 2 inhibitor dapagliflozin decrease...

1. A. The sodium-glucose transporter-2 (SGLT-2) inhibitors, empaglifloxin (Jardiance®), dapagliflozin (Farxiga®), and canagliflozin (Invokana®) inhibit proximal tubular glucose reabsorption resulting in renal glucosuria. These drugs can cause weight loss, natriuresis with volume depletion, hypotension, bacterial or fungal UTI, and ketoacidosis even in Type 2 diabetics. Ketoacidosis is more like...

Canagliflozin, dapagliflozin and empagliflozin, all recently approved for treatment of Type 2 diabetes, were derived from the natural product phlorizin. They reduce hyperglycemia by inhibiting glucose reuptake by SGLT2 in the kidney, without affecting intestinal glucose uptake by SGLT1. We now report that canagliflozin also activates AMP-activated protein kinase (AMPK), an effect also seen with...

Because dapagliflozin has been shown to induce glycosuria, patients should be warned about the most common clinical sequelae of osmotic diuresis, hypotension, and hypoglycemia. Systolic blood pressure typically decreases by 2.3 to 5.6 mm Hg. However, hypotension is relatively uncommon (number needed to harm [NNH] = 337) and mainly affects older adults, patients on loop diuretics, and those with...